FIELD: organic chemistry, pharmacy. SUBSTANCE: composite comprises pharmaceutical carrier and novel crystalline γ-modification of n-butylaminobenzoic acid 2-dimethylaminoethyl ester hydrochloride (dicaine). Crystalline γ-modification of dicaine exhibits melting point (149.5 ± 0.4) C and definite values of diffraction maxima and their relative intensities. The proposed composite as compared with composites based on the known modifications of dicaine ensures to prolong anesthesia period, decrease onset time of anesthesia being without by-side effects. Invention can be used in ophthalmology, microsurgery and stomatology as a topical anesthetic agent. EFFECT: valuable medicinal properties. 2 cl, 2 tbl
Authors
Dates
2002-12-20—Published
2001-11-12—Filed